Citations

Clear

861 citation(s) found for "Sd, Wexner".

The Fourth Annual Symposium of the Midwest Aging Consortium
Kim, Jinoh , Buffenstein, Rochelle , Vanegas, Natalia-Del Pilar , Agudelo-Garcia, Paula A., Rojas, Mauricio , Englund, Davis A. , Nunes, Allancer , Kohut, Marian L. , Kothadiya, Siddhant , Bardhan, Rizia , Camell, Christina D. , Sturmlechner, Ines , Lamming, Dudley W. , Leiser, Scott F. , Escorcia, Wilber , Gill, Matthew S. , Helfand, Stephen L., Korm, Sovannarith , Pehar, Mariana , Blaszkiewicz, Magdalena , McGregor, Eric R. , Stilgenbauer, Lukas , Taylor, Alicia , McNeill, Elizabeth M. , Sturmlechner, Ines , Lamming, Dudley W , Anderson, Rozalyn M , Bai, Hua , Englund, Davis A. , Bronikowski, Anne M. , Rosas, Lorena , Mora, Ana Lucia , LeBrasseur, Nathan K. , Robbins, Paul D. , Goronzy, Jörg J. , Yeh, Chung‐Yang , Huang, Shijiao , Taylor, Jackson R. , Gribble, Kristin E. , Townsend, Kristy L. , Anderson, Rozalyn M. , Sadagurski, Marianna , Stoeger, Thomas

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | November 5, 2024 | Volume: 79 | Issue: 11 | Pages: No page available

10.1093/gerona/glae236 | PMID 39498863 Get It

Abstract The Midwest Aging Consortium (MAC) has emerged as a critical collaborative initiative aimed at advancing our understanding of aging and developing strategies to combat the rising prevalence of age-related diseases. Founded in 2019, MAC brings together researchers from various disciplines and institutions across the Midwestern United States to foster interdisciplinary geroscience research. This report summarizes the highlights of the Fourth Annual Symposium of MAC, which was held at Iowa State University in May 2023. The symposium featured presentations on a wide array of topics, including studies on slow-aging animals, cellular senescence and senotherapeutics, the role of the immune system in aging, metabolic changes in aging, neuronal health in aging, and biomarkers for measuring the aging process. Speakers shared findings from studies involving a variety of animals, ranging from commonly used species such as mice, rats, worms, yeast, and fruit flies, to less-common ones like naked mole-rats, painted turtles, and rotifers. MAC continues to emphasize the importance of supporting emerging researchers and fostering a collaborative environment, positioning itself as a leader in aging research. This symposium not only showcased the current state of aging biology research but also highlighted the consortium’s role in training the next generation of scientists dedicated to improving the healthspan and well-being of the aging population.
Imposter Syndrome Across Surgical Subspecialties: Scratching the Surface
Brown, R.F. , Posid, Tasha , Lund, Sarah , L'Hullier, Joseph C, Sheppard, Olabisi Ololade , Zhang, J. , Zoumpou, Theofano , Bialowas, Christie , Hendershot, Kimberly, Cooper, Amanda Beth , Wu, Esther , Zhang, Jeannette, McKinley, Sophia K. , Wieck, Minna M.

Mayo Clinic

No container title available | November 4, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5257288/v1 Get It

Abstract Purpose Imposter syndrome (IS) is a “behavioral health phenomenon described as self-doubt of intellect, skills, or accomplishments among high-achieving individuals” that has been associated with psychological distress, burnout, anxiety, and depression, and has also been shown to negatively impact career retention and job performance. Previous studies, while rare, have demonstrated remarkably high rates of IS amongst surgical trainees, but include little information on contributing factors. The purpose of this study was to broadly explore IS in surgical trainees across specialties.Methods An anonymous electronic survey aimed at identifying the prevalence, severity, and underlying factors contributing to IS in surgical trainees was developed by members of the ASE Graduate Surgical Education Committee and distributed to list servs of surgical residents across specialties at twelve institutions. Descriptive statistics, univariate analysis, and multivariable analysis were performed to identify differences in and factors contributing to IS.Results A total of 155 survey responses were received. Seventy-one percent of respondents report significant or intense IS, with women demonstrating more severe IS. Residents identified interactions with peers or other residents as triggering more feelings of IS compared to faculty or patients. Prior IS training, feeling a sense of belonging in residency, and lower incidence of microaggressions were associated with less severe IS.Conclusions IS remains prevalent and severe amongst surgical trainees. Although previous work has identified many personal factors that contribute to IS, this study is one of the first of its kind to identify environmental and experiential (context-dependent) factors associated with more severe IS.
S136 Obesity Is Associated With Worsened Endoscopic Outcomes in Patients With Pancreatic Collections and Should Be Integrated Into the QNI Classification
Baroud, Serge , Annan, Karim Al , Mrad, Rudy , Han, Sam , Law, Ryan , Bofill-García, Aliana, Martin, John A. , Petersen, Bret T. , Vege, Santhi Swaroop , Kerbage, Anthony , AbiMansour, Jad P. , Vargas, Eric J. , Storm, Andrew C. , Chandrasekhara, Vinay , Petersen, Bret T. , Bazerbachi, Fateh , Majumder, Shounak , Dayyeh, Barham K. Abu

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S102-S103

10.14309/01.ajg.0001028912.11285.a9 Get It

P12.09.A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Hanft, Simon , Elder, B L, Giglio, Pierre , Wu, Siqi , Farrell, Christopher , Alnahhas, Iyad , Lee, I-Y., Walbert, Tobias , Boockvar, John A. , Aregawi, Dawit , Kim, L., Schulder, Michael , Singer, S, Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Jeyapalan, Suriya, Magge, Rajiv , Agarwal, Vijay , Amankulor, N, Quinones-Hinojosa, A, Neese, Laura L., Scott, Charles , Pérez‐Ollé, Raül, Andrews, David , Lee, Ian , Lee, Ian Y , Elder, B, Lee, I Y, Vojnic, Morana , Zacharia, Brad E. , Kim, L., Ghatan, Saadi , Wu, J, Patel, Nitesh V. , Bhatia, Ankush , Brennan, Cameron , Evans, L, Gill, B, Sengupta, Soma , Wong, Eric T. , Amankulor, N, Quinones-Hinojosa, A, Andrews, D

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v67-v68

10.1093/neuonc/noae144.222 Get It

Abstract BACKGROUND Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax has utilized its Goldspire™ platform to create IGV-001, an autologous biologic-device combination product for the treatment of newly diagnosed GBM (ndGBM). IGV-001 consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated and administered via biodiffusion chambers implanted in the abdomen. Together, these components stimulate immunogenic cell death and antigen release. In a phase 1b study in patients with ndGBM, IGV-001 was well tolerated without unexpected adverse events. Multiple efficacy signals were also observed, including significant improvements in progression-free survival, overall survival, radiographic evidence of tumor response, and changes in immune response biomarkers. A phase 2b randomized, multicenter, double-blind, placebo-controlled study to assess the safety and efficacy of IGV-001 in patients with ndGBM (ClinicalTrials.gov identifier: NCT04485949) is ongoing. Here, we present the first safety data from the study. MATERIAL AND METHODS After surgical resection, patients are treated with IGV-001 or placebo followed by SOC. The study will enroll approximately 93 patients at 20 sites in the United States, with a 2:1 randomization favoring IGV-001. The primary outcome is progression-free survival, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include overall survival, defined as the time from randomization to death due to any cause, and safety. RESULTS As of February 2, 2024, a total of 72 patients have been randomized and 69 have been implanted with IGV-001 or placebo plus SOC. The median age was 60.0 years (range, 24-70 years). Most randomized patients (76.4%) were 51-70 years of age, and the male:female ratio was 2.27. A total of 39/45 (86.7%) patients with enough follow-up time, initiated treatment with concurrent radiation and temozolomide. A total of 9/72 (12.5%) randomized patients discontinued treatment, including 7 patients who discontinued during the SOC treatment period. No patients discontinued treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized patients discontinued the study after randomization. CONCLUSION To date, the review of blinded safety data did not show any emerging risk and supports that there is no change to the benefit-risk profile of treatment with IGV-001 versus placebo. The data will be updated before presentation.
Genomic imprinting biomarkers for cervical cancer risk stratification
Bai, Peng, Chen, Ying , Qin, Zhengwen, Cheng, Tong , Pineda, John , Shi, Panying, Wang, Xiaonan , Wang, Jianhong, Xu, Lian , Zheng, Huixian, Lin, Wenyi , Huang, Wenbin , Shen, Rulong , Yue, Changjun, Xu, Hui‐Xiong , Zhou, Ning , Zhang, Yaoyao , Liu, Hanmin , Xiao, Xue , Wang, Wei , Xing, Li , Wang, Xiaonan, Gao, Xuemei , Yang, Lulu , Batalini, Felipe , Liu, Yang

Mayo Clinic

Cancer Communications | October 10, 2024 | Volume: 44 | Issue: 12 | Pages: 1385-1390

10.1002/cac2.12617 | PMID 39388677 Get It

Behind the curtain: conflicts of interest in spinal cord stimulation trials—an infographic
D’Souza, Ryan S. , Klasova, Johana, Hussain, Nasir , D'Souza, Ryan S

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 8, 2024 | Volume: 51 | Issue: 2 | Pages: 218-218

10.1136/rapm-2024-106069 | PMID 39379325 Get It

Hidden influence? Unmasking conflicts of interest from randomized clinical trials on spinal cord stimulation for chronic pain
D’Souza, Ryan S. , Klasova, Johana, Kleppel, Donald J , Hussain, Nasir , Hussain, Nasir , D'Souza, Ryan S , Prokop, Larry J.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 7, 2024 | Volume: 51 | Issue: 1 | Pages: 17-24

10.1136/rapm-2024-105903 | PMID 39379095 Get It

Background Randomized clinical trials (RCTs) are considered the gold standard for evaluating the efficacy of healthcare interventions. However, conflicts of interest (COIs) can compromise the scientific integrity in these trials. This study characterized COIs in RCTs on spinal cord stimulation for chronic pain, focusing on the prevalence, disclosure, and monetary value of COIs. Methods This cross-sectional study analyzed RCTs published from January 1, 2013 to July 27, 2023. Primary outcomes included the presence, disclosure, and monetary value of COIs, while secondary outcomes assessed the presence of direct/indirect COIs, sponsor access to data, and associations between COIs and select variables, including journal impact factor, publication year, and study outcomes. Results Of 38 RCTs, 30 (78.9%) reported COIs. On average, 35.6% of authors per RCT had at least one COI, with a mean of 0.7 COIs per author. The mean annual monetary value of COIs was US$41,157.83 per author per RCT. 29 RCTs (76.3%) had undisclosed COIs, with an average of 24.2% of authors per RCT having undisclosed COIs. Sponsor access to data was reported in 67.6% of RCTs. No associations were observed between the mean percentage of authors with COIs and the monetary value of COIs and select dependent variables (impact factor, publication year, and study outcomes). Conclusions A substantial majority of RCTs reported COIs with many authors having undisclosed conflicts, highlighting the need for stringent COI disclosure guidelines to maintain research integrity. Expanding COI registry systems globally and increasing non-industry funding are crucial steps toward enhancing transparency and reducing biases in medical research.
9295 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Harmatz, Paul , Warren, Mark , Ma, Nina, Khan, Aliya , Lemoine, Sandrine, Mantovani, Giovanna, Wasserman, Halley , Barbosa, Ana Paula , Cardot-Bauters, Catherine, Roberts, Mary Scott , Mathew, Arun, Adler, Scott, Zillikens, Maria Carola, Ing, Steven , Mora, Stefano , Imel, Erik Allen , Tebben, Peter J. , Palermo, Andrea, Decallonne, Brigitte , Lemoine, Sandrine , Linglart, Agnès , Barbosa, Ana Paula, Clifton-Bligh, Roderick , Rejnmark, Lars

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.383 Get It

Abstract Disclosure: S.W. Ing: Advisory Board Member; Self; Ultragenyx, Amolyt. Grant Recipient; Self; Alexion Pharmaceuticals, Inc.. Research Investigator; Self; BridgeBio Pharma, Takeda, Amolyt, Radius Health, Inc, Ultragenyx. P. Harmatz: Research Investigator; Self; BridgeBio Pharma. S. Mora: Research Investigator; Self; BridgeBio Pharma. E.A. Imel: Research Investigator; Self; BridgeBio Pharma. P.J. Tebben: Research Investigator; Self; BridgeBio Pharma. M.L. Warren: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt. Speaker; Self; Ascendis. N. Ma: Research Investigator; Self; Calcilytix Therapeutics, Ultragenyx, Inozyme. Other; Self; Up To Date. A.A. Khan: Research Investigator; Self; BridgeBio Pharma, Ascendis. A. Palermo: Research Investigator; Self; BridgeBio Pharma. B. Decallonne: Research Investigator; Self; BridgeBio Pharma. S. Lemoine: Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. G. Mantovani: Research Investigator; Self; BridgeBio Pharma. A. Linglart: Consulting Fee; Self; Alexion, Novo Nordisk, Merck, Pfizer, Inc.. Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. H. Wasserman: Research Investigator; Self; BridgeBio Pharma. A.P. Barbosa: Research Investigator; Self; BridgeBio Pharma. C. Cardot-bauters: Research Investigator; Self; BridgeBio Pharma. M. Roberts: Employee; Self; BridgeBio Pharma. A. Mathew: Employee; Self; BridgeBio Pharma. S. Adler: Employee; Self; BridgeBio Pharma. M.C. Zillikens: Research Investigator; Self; BridgeBio Pharma. R.J. Clifton-Bligh: Consulting Fee; Self; Ipsen, Kyowa Kirin, Amgen Inc, Eisai. Research Investigator; Self; BridgeBio Pharma. L. Rejnmark: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt, Takeda, Kyowa Kirin. Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone (PTH) concentrations, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. While a rare disease, ADH1 is one of the more frequently identified causes of genetic hypoparathyroidism. Conventional therapy includes calcium (Ca) and/or active vitamin D, but this regimen incompletely corrects the hypocalcemia and is associated with persistent hypercalciuria, which may result in renal complications including nephrocalcinosis (NC), nephrolithiasis (NL), and chronic kidney disease (CKD). The CLARIFY disease monitoring study [NCT05227287] is a global, multicenter, longitudinal study to understand disease burden, management, and progression in children and adults with ADH1 over a 5-year period. Here we report data on the characteristics of adult participants at study entry. As of November 2023, 45 adults (≥18 years) with ADH1 were enrolled, with a mean±SD age of 42.1±16.5 years (range 18-80). The mean±SD age of a hypocalcemia diagnosis was 19.1±19.1 years, while the mean±SD age for a diagnosis of ADH1 was 28.2±20.6 years. As reported on medical history, in decreasing order of prevalence, 36% (16) had NC, 22% (10) had intracranial calcifications, 11% (5) had history of seizures, 11% (5) had CKD, 9% (4) had cataracts, 7% (3) had NL, and 4% (2) had undergone renal transplant. Treatment data were available for 43 participants and included the following: 74% (32) Ca and active vitamin D, 9% (4) Ca alone, 9% (4) active vitamin D alone, 37% (16) magnesium, 33% (14) thiazide diuretics, 26% (11) potassium, 7% (3) phosphate binder, 7% (3) PTH, and 5% (2) no treatment. Mean±SD fasting values collected prior to conventional therapy dose are presented. PTH concentrations (10.1±8.2 pg/mL [nl 15-65]) and albumin-corrected calcium ([cCa]=7.5±1.0 mg/dL [nl 8.5-10.5]) were low. Despite the low mean cCa, the mean 24-hr urine calcium was elevated (268±183 mg/d, [nl <250 women, <300 men]). Blood phosphate was 4.8±0.8 mg/dL [nl 2.5-4.8] while blood magnesium was 1.8±0.2 mg/dL [nl 1.8-2.4]. 25-OH vitamin D was 35.0±13.5 ng/mL [nl 30-80]. Renal function as assessed by CKD-EPIcr_R showed eGFR of 86±23 mL/min/1.73m² (range 36-123). This study represents the largest cohort of adults with ADH1 described to date. These data highlight variability in therapeutic approaches in a real-world setting with some participants receiving up to 6 different medications/supplements. Despite being followed in expert centers, and treated with available therapies, patients on average have low cCa with relatively high 24-hr urine calcium excretion. The CLARIFY study provides an opportunity to better understand the progression and burden of disease in participants with ADH1. Presentation: 6/3/2024
8669 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Harmatz, Paul , Warren, Mark , Ma, Ning , Khan, Aliya , Mantovani, Giovanna, Barbosa, Arsénio, Cardot‐Bauters, C., Roberts, Mary Scott , Adler, Scott, Ing, Steven , Mora, Stefano , Imel, Erik Allen , Tebben, Peter J. , Ma, N, Palermo, A, Decallonne, Brigitte , Lemoine, Sandrine , Linglart, Agnès , Wasserman, H, Barbosa, A P, Mathew, A, Zillikens, M. Carola , Clifton-Bligh, Roderick , Rejnmark, Lars

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.384 Get It

Abstract Disclosure: S.W. Ing: Research Investigator; Self; BridgeBio Pharma. P. Harmatz: Research Investigator; Self; BridgeBio Pharma. S. Mora: Research Investigator; Self; BridgeBio Pharma. E.A. Imel: Research Investigator; Self; BridgeBio Pharma. P.J. Tebben: Research Investigator; Self; BridgeBio Pharma. M.L. Warren: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt. Speaker; Self; Ascendis. N. Ma: Research Investigator; Self; Calcilytix Therapeutics, Ultragenyx, Inozyme. Other; Self; Up To Date. A.A. Khan: Research Investigator; Self; BridgeBio Pharma, Ascendis. A. Palermo: Research Investigator; Self; BridgeBio Pharma. B. Decallonne: Research Investigator; Self; BridgeBio Pharma. S. Lemoine: Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. G. Mantovani: Research Investigator; Self; BridgeBio Pharma. A. Linglart: Consulting Fee; Self; Alexion, Novo Nordisk, Merck, Pfizer, Inc.. Research Investigator; Self; BridgeBio Pharma, Kyowa Kirin. H. Wasserman: Research Investigator; Self; BridgeBio Pharma. A.P. Barbosa: Research Investigator; Self; BridgeBio Pharma. C. Cardot-bauters: Research Investigator; Self; BridgeBio Pharma. M. Roberts: Employee; Self; BridgeBio Pharma. A. Mathew: Employee; Self; BridgeBio Pharma. S. Adler: Employee; Self; BridgeBio Pharma. M.C. Zillikens: Research Investigator; Self; BridgeBio Pharma. R.J. Clifton-Bligh: Consulting Fee; Self; Ipsen, Kyowa Kirin, Amgen Inc, Eisai. Research Investigator; Self; BridgeBio Pharma. L. Rejnmark: Research Investigator; Self; BridgeBio Pharma, Ascendis, Amolyt, Takeda, Kyowa Kirin. Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone (PTH) concentrations, hypocalcemia, hypercalciuria, hyperphosphatemia and hypomagnesemia. While a rare disease, ADH1 is one of the more frequently identified causes of genetic hypoparathyroidism. Conventional therapy includes calcium (Ca) and/or active vitamin D, but this regimen incompletely corrects the hypocalcemia and is associated with persistent hypercalciuria, which may result in renal complications including nephrocalcinosis (NC), nephrolithiasis (NL), and chronic kidney disease (CKD). The CLARIFY disease monitoring study [NCT05227287] is a global, multicenter, longitudinal study to understand disease burden, management, and progression in children and adults with ADH1 over a 5-year period. Here we report data on the characteristics of adult participants at study entry. As of November 2023, 45 adults (≥18 years) with ADH1 were enrolled, with a mean±SD age of 42.1±16.5 years (range 18-80). The mean±SD age of a hypocalcemia diagnosis was 19.1±19.1 years, while the mean±SD age for a diagnosis of ADH1 was 28.2±20.6 years. As reported on medical history, in decreasing order of prevalence, 36% (16) had NC, 22% (10) had intracranial calcifications, 11% (5) had history of seizures, 11% (5) had CKD, 9% (4) had cataracts, 7% (3) had NL, and 4% (2) had undergone renal transplant. Treatment data were available for 43 participants and included the following: 74% (32) Ca and active vitamin D, 9% (4) Ca alone, 9% (4) active vitamin D alone, 37% (16) magnesium, 33% (14) thiazide diuretics, 26% (11) potassium, 7% (3) phosphate binder, 7% (3) PTH, and 5% (2) no treatment. Mean±SD fasting values collected prior to conventional therapy dose are presented. PTH concentrations (10.1±8.2 pg/mL [nl 15-65]) and albumin-corrected calcium ([cCa]=7.5±1.0 mg/dL [nl 8.5-10.5]) were low. Despite the low mean cCa, the mean 24-hr urine calcium was elevated (268±183 mg/d, [nl <250 women, <300 men]). Blood phosphate was 4.8±0.8 mg/dL [nl 2.5-4.8] while blood magnesium was 1.8±0.2 mg/dL [nl 1.8-2.4]. 25-OH vitamin D was 35.0±13.5 ng/mL [nl 30-80]. Renal function as assessed by CKD-EPIcr_R showed eGFR of 86±23 mL/min/1.73m² (range 36-123). This study represents the largest cohort of adults with ADH1 described to date. These data highlight variability in therapeutic approaches in a real-world setting with some participants receiving up to 6 different medications/supplements. Despite being followed in expert centers, and treated with available therapies, patients on average have low cCa with relatively high 24-hr urine calcium excretion. The CLARIFY study provides an opportunity to better understand the progression and burden of disease in participants with ADH1. Presentation: 6/3/2024
Anterior Cruciate Ligament Injury Does Not Increase the Risk for a Future Concussion: A Unidirectional Phenomenon
McPherson, April L. , Larson, Dirk R. , Shirley, Matthew B., Dancy, Malik E. , Schilaty, Nathan D. , Bates, Nathaniel A , Schilaty, Nathan D , Larson, Dirk , Bates, Nathaniel A.

Mayo Clinic

Journal of Sport Rehabilitation | September 25, 2024 | Volume: 34 | Issue: 3 | Pages: 264-270

10.1123/jsr.2024-0030 | PMID 39322214 Get It

Context: Epidemiological studies have shown an increased risk of musculoskeletal injury after concussion. The purpose of this study was to determine whether the reverse relationship exists, specifically whether there is an increased risk of concussion after an anterior cruciate ligament (ACL) injury in a population-based cohort. Design: Retrospective cohort. Methods: The Rochester Epidemiology Project was searched between 2000 and 2017 for International Classification of Diseases, 9th and 10th Revision codes relevant to the diagnosis and treatment of concussion and ACL tear. A total of 1294 unique patients with acute, isolated ACL tears and no previous history of concussion were identified. Medical records for cases were reviewed to confirm ACL tear diagnosis and to determine history of concussion after the ACL injury. Cases were matched by age, sex, and Rochester Epidemiology Project availability to patients without an ACL tear (1:3 match), resulting in 3882 controls. Medical records of matched control patients were reviewed to rule out history of ACL injury. The hazard ratio of concussion injury following an ACL injury was determined. Results: Nine patients with an ACL injury suffered concussion up to 3 years after the ACL injury. The rate of concussion was no different between ACL-injured cases (0.7%) compared with matched controls with no ACL injury (1.2%), which corresponded to a hazard ratio of 0.55 (95% confidence interval, 0.3–1.1; P = .10). Conclusions: Based on the current evidence, there does not appear to be a significant association between ACL injury and subsequent concussion, which suggests that a concussion uniquely affects the risk of future subsequent musculoskeletal injury.